Trimodulin

DRUG3 trials

Sponsors

Biotest

Conditions

Acute Respiratory Distress SyndromeBacterial PneumoniaCOVID-19Community-acquired PneumoniaCovid19Fungal PneumoniaPneumoniaRespiratory Infection

Phase 2

Efficacy and Safety of Trimodulin in Subjects With Severe COVID-19

CompletedNCT04576728

Start: 2020-10-06End: 2021-06-29Updated: 2023-01-10

Phase 3

Efficacy and Safety of Trimodulin (BT588) in Subjects With CAP Including COVID-19 Pneumonia

TerminatedNCT05531149

BiotestAcute Respiratory Distress Syndrome, Bacterial Pneumonia, Community-acquired Pneumonia +5

Start: 2022-12-22End: 2025-05-05Updated: 2025-06-08

Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)

RecruitingNCT05722938

BiotestCommunity-acquired Pneumonia

Start: 2023-09-09End: 2028-07-31Target: 590Updated: 2026-09-14

Related Papers

Efficacy and safety of trimodulin in patients with severe COVID-19: results from a randomised, placebo-controlled, double-blind, multicentre, phase II trial (ESsCOVID)

European journal of medical research2024-08-133 citations